Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

Vertex delivered a split result this morning that left investors parsing mixed signals. The tax technology provider beat on EPS but missed revenue expectations. Shares were down nearly 10% by the ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...

(RTTNews) - Vertex, Inc. (VERX) revealed a profit for third quarter that Decreased from last year but beat the Street estimates. The company's bottom line came in at $4.04 million, or $0.02 per share.

The X-Men '97 team isn’t done breaking hearts just yet. Speaking exclusively with Collider’s Maggie Lovitt at New York Comic Con, Marvel TV boss Brad Winderbaum shed new light on one of the show’s ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Add Yahoo as a preferred source to see more of our stories on Google. Renowned SFX and makeup artist Gi Ponci recently posted a picture of an official Avengers: Doomsday merch that featured as many as ...

Renowned SFX and makeup artist Gi Ponci recently posted a picture of an official Avengers: Doomsday merch that featured as many as 28 confirmed characters from the film. The image not only served as a ...

Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...